US Patent 10358421 Piperidine derivatives as HDAC1/2 inhibitors
Patent 10358421 was granted and assigned to Regenacy Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 11 Dec, 2023
Megan Gustafson
Edits made to:
Infobox (+1/-1 properties)
Infobox
Current Assignee
0
Current Assignee
Megan Gustafson
Edits made to:
Infobox (+1/-1 properties)
Infobox
Patent Applicant
0
Patent Applicant
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+212 characters)
Article
Patent abstract
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
John H. van Duzer0
Ralph Mazitschek0
Edits on 19 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
103584210
Date of Patent
July 23, 2019
0Patent Application Number
157009980
Date Filed
September 11, 2017
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 27 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10358421 Piperidine derivatives as HDAC1/2 inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10358421
Date of patent
July 23, 2019
Patent application number
15700998
Date Filed
September 11, 2017
Patent primary examiner
Find more entities like US Patent 10358421 Piperidine derivatives as HDAC1/2 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
